Stay updated on Nivolumab Plus Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-status notice, older Revision: v3.4.1 reference, and melanoma-related topic tags.
    Difference
    0.3%
    Check dated 2026-02-11T06:18:06.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide funding-status notice banner was added to the page, directing users to cc.nih.gov and opm.gov for updates, and the version tag shows Revision: v3.4.1 replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-04T05:14:30.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    UI changes include adding a glossary toggle and updating metadata labels: Last Update Submitted that Met QC Criteria and Revision: v3.4.0, while older labels such as Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed or adjusted. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-28T03:25:05.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Added Melanoma as a condition and linked MedlinePlus Genetics related topics. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-21T01:20:19.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4, replacing the previous v3.3.3, which is a minor update with no visible impact on study content or functionality — To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:39:32.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Added new Locations and regional entries (Australian Capital Territory, New South Wales, Northern Territory, Queensland, South Australia, Tasmania, Victoria, Western Australia, Rhineland-palladium, Greater London, Tyne and Wear) to the study page. Removed HHS Vulnerability Disclosure, Melanoma, MedlinePlus Genetics, and several location groupings (Australian Capital Territory Locations, New South Wales Locations, Northern Territory Locations, Queensland Locations, South Australia Locations, Tasmania Locations, Victoria Locations, Western Australia Locations, Rhineland-palladium Locations, Greater London Locations, Tyne and Wear Locations) with an updated revision tag.
    Difference
    0.7%
    Check dated 2025-12-23T22:50:29.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.